Pulmonary Vascular Disease News

The FDA approved the SPIRARE II trial set to evaluate the use of Jupiter Endovascular’s Vertex Pulmonary Embolectomy System with Endoportal Control in patients with acute pulmonary embolism, according to a press release.

When presented with four unlabeled treatment profiles showing five treatment attributes, 96% of patients with pulmonary arterial hypertension chose a single-tablet vs. a multi-tablet combination therapy, according to a poster.

Around 7 months after not meeting the Prescription Drug User Fee Act goal date for Yutrepia, the FDA has tentatively approved the drug for pulmonary arterial hypertension and pulmonary hypertension-associated interstitial lung disease.

Inari Medical has issued a recall and update to the instructions for use of its 30 mm thrombectomy catheter due to risk for injury and death from device entrapment and pulmonary emboli.

Two machine learning-based models using only medical record data had high accuracy in detecting individuals with and without pulmonary embolism at hospital admission, according to results published in Journal of Medical Internet Research.

Health care professionals treating patients with pulmonary arterial hypertension recommend individualized dosing and titration of oral selexipag, according to a poster presented at the International Pulmonary Hypertension Conference.

The FDA granted orphan drug designation to ZMA001 as a treatment for patients with pulmonary arterial hypertension, according to a press release from Zymedi.

Adults with obstructive sleep apnea treated with CPAP for 24 weeks had improved vascular inflammation and lower unstable plaque volume, according to results published in Annals of the American Thoracic Society.

An AI algorithm had high discriminative ability in identifying pulmonary hypertension-likely patients from control patients at and before diagnosis using electrocardiogram data, according to study results.

SAN DIEGO — Among patients with pulmonary arterial hypertension, seralutinib lowered pulmonary vascular resistance over 72 weeks, according to research presented at the American Thoracic Society International Conference.